Generics, Budgeting, And The Stubborn Persistence Of Cost Savings
Executive Summary
ANDA sponsors want inflation penalty in Medicaid repealed, but long struggle to eliminate IPAB shows just how hard it may be for generics industry to get that 'fix'.
You may also be interested in...
Medicare Part D Drug Price Policies May Offer Financial Trade-Offs
Higher manufacturer discounts required in donut hole under new budget law could offset somewhat by point-of-sale rebates in Part D, which are expected to be included in President Trump's FY 2019 budget proposal.
The Greatest FDA Advisory Committees Of All Time Part IV: Neurology Lays Claim To The Crown
We look back at another of the greatest FDA advisory committees of the last 20 years. This time: the nearly 12-hour meeting in 2016 on Sarepta’s eteplirsen for Duchenne muscular dystrophy.
Are Regulators Ready For The Robot Era? ChatGPT Weighs In On EU Regulation
Artificial intelligence model’s comments signal the likely start of computer-generated comments to the US FDA’s public notices.